Cambridge Healthtech Institute's Genome Tri-Conference

James W. Larkin jamesl at healthtech.com
Thu Sep 25 13:20:07 EST 1997


Cambridge Healthtech Institute's Genome Tri-Conference

Fifth Annual
HUMAN GENOME PROJECT: Commercial Implications
February 9-11, 1998

As the Human Genome Project gears up into the
sequencing phase, the expectations for translating such
data into valuable information increase. While automated
gel-based sequencing remains the workhorse of this
effort, newer approaches have moved much closer to
becoming practical. Much greater emphasis is also being
placed on software for analyzing sequences and the
creation of gene expression libraries and databases. Such
databases, in combination with analysis of gene function,
will play a key role in the identification of novel targets
for diagnostic and therapeutic applications. The third day
of this meeting will again feature case studies of genomic
data-based drug development efforts. This meeting has
become established as a key forum for academic and
commercial researchers to discuss and find out about the
latest technology and applied developments in the
genomics field.


Second Annual
GENE FUNCTIONAL ANALYSIS
February 12-13, 1998

As the complete genomes of the first model organisms
become available, it is now possible to explore how well
such data can be interpreted in terms of functional
analysis. The sheer volume of genetic sequence is going
to require a paradigm shift from laborious determination
of function for one gene at a time to high-throughput
approaches that can automatically assist in such efforts,
via homology and cross-species comparisons. The use of
libraries of mutants or knockouts also represents a key
approach toward faster analysis. Efforts to determine
function of gene sequences and relate them to genetic
pathways and roles in disease will be key for exploiting
genetic information for medicinal purposes.


GENOMIC OPPORTUNITIES: Emerging and Early Stage Partners
February 14-15, 1998 

The growing role of genomics in diagnostics and
therapeutic development, along with dramatic advances
in technological developments, is fueling the formation of
new companies designed to exploit these opportunities.
This program showcases several dozen impressive
startup companies in a format suitable for comparison
and networking. The intended audience includes
pharmaceutical companies and more established genomic
companies that are looking for partnering possibilities
that would enhance their own development efforts.
Investors and analysts will also find the program to be
rich in potential for consideration.   

For more information, please contact:

Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls,  MA  02164
USA

Phone: 617-630-1300
Fax: 617-630-1325
e-mail: chi at healthtech.com
http://www.healthtech.com/conferences/





More information about the Bio-soft mailing list